Frontline Considerations for Immunotherapy in Endometrial Cancer

Panelists discuss how clinicians can evaluate multiple factors when determining immunotherapy use in the first-line recurrent or metastatic endometrial cancer setting. They examine how tumor molecular subtype, prior therapies, patient comorbidities, and tolerability concerns influence regimen selection. The conversation highlights the increasing importance of multidisciplinary decision-making as treatment landscapes evolve.

Experts emphasize the need to balance efficacy with safety, considering how immune-related toxicities may affect long-term quality of life. They describe practical considerations such as assessing PD-L1 status, microsatellite instability, and mismatch repair deficiency, as well as emerging biomarkers that may refine treatment choice. Additionally, they review data supporting combination therapy versus single-agent strategies depending on disease burden and patient fitness.

In the concluding discussion, panelists stress the significance of tailoring therapy to the individual, rather than applying a one-size-fits-all model. They advocate for patient education, shared decision-making, and awareness of clinical trial opportunities that may expand future options for personalized care.